CLINICAL TRIALS PROFILE FOR THIOLA

All Clinical Trials for THIOLA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01095731 ↗	The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage	Completed	Food and Drug Administration (FDA)	Phase 2	2010-04-01	The purpose of this phase II study is to further assess the safety of tiopronin in aneurysmal subarachnoid hemorrhage(aSAH) patients in order to obtain preliminary data on the efficacy of tiopronin versus placebo in reducing serum and cerebrospinal fluid (CSF) 3AP levels in this patient population. Funding Source - FDA Office of Orphan Products Development
NCT01095731 ↗	The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage	Completed	University of Florida	Phase 2	2010-04-01	The purpose of this phase II study is to further assess the safety of tiopronin in aneurysmal subarachnoid hemorrhage(aSAH) patients in order to obtain preliminary data on the efficacy of tiopronin versus placebo in reducing serum and cerebrospinal fluid (CSF) 3AP levels in this patient population. Funding Source - FDA Office of Orphan Products Development
NCT01095731 ↗	The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage	Completed	University of Washington	Phase 2	2010-04-01	The purpose of this phase II study is to further assess the safety of tiopronin in aneurysmal subarachnoid hemorrhage(aSAH) patients in order to obtain preliminary data on the efficacy of tiopronin versus placebo in reducing serum and cerebrospinal fluid (CSF) 3AP levels in this patient population. Funding Source - FDA Office of Orphan Products Development
NCT01095731 ↗	The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage	Completed	E. Sander Connolly	Phase 2	2010-04-01	The purpose of this phase II study is to further assess the safety of tiopronin in aneurysmal subarachnoid hemorrhage(aSAH) patients in order to obtain preliminary data on the efficacy of tiopronin versus placebo in reducing serum and cerebrospinal fluid (CSF) 3AP levels in this patient population. Funding Source - FDA Office of Orphan Products Development

Clinical Trial Conditions for THIOLA

Condition Name

Condition Name for THIOLA
Intervention	Trials
Aneurysmal Subarachnoid Hemorrhage	1

Condition MeSH

Condition MeSH for THIOLA
Intervention	Trials
Subarachnoid Hemorrhage	1
Hemorrhage	1

Clinical Trial Locations for THIOLA

Trials by Country

Trials by Country for THIOLA
Location	Trials
United States	3

Trials by US State

Trials by US State for THIOLA
Location	Trials
Washington	1
New York	1
Florida	1

Clinical Trial Progress for THIOLA

Clinical Trial Phase

Clinical Trial Phase for THIOLA
Clinical Trial Phase	Trials
Phase 2	1

Clinical Trial Status

Clinical Trial Status for THIOLA
Clinical Trial Phase	Trials
Completed	1

Clinical Trial Sponsors for THIOLA

Sponsor Name

Sponsor Name for THIOLA
Sponsor	Trials
Food and Drug Administration (FDA)	1
University of Florida	1
University of Washington	1

Sponsor Type

Sponsor Type for THIOLA
Sponsor	Trials
Other	3
U.S. Fed	1